Breaking News Instant updates and real-time market news.

MYL

Mylan

$36.66

0.19 (0.52%)

10:32
10/02/18
10/02
10:32
10/02/18
10:32

Morning call buyer in Mylan

Morning call buyer in Mylan. Shares up 14c to $36.62 and Jan 40s trade in small lots from $1.17 to 1.20 before 8.6K bought for $1.22. An even 10K opened early-Tuesday and the call option, which has a strike price 9.2% above the stock price, captures one earnings report in early-November. Shares edged up 1.8% to $39.23 on 8/8/18 after the last report, but thanks to a six-day losing skid prior to today's uptick, has shed 6.5% since that time. The Jan 40 call buyer Tuesday seems to be anticipating another leg higher through earnings and into early-2019.

  • 13

    Nov

MYL Mylan
$36.66

0.19 (0.52%)

09/19/18
LEER
09/19/18
NO CHANGE
LEER
Outperform
Leerink 'incrementally positive on state of generics industry following meetings
Leerink analyst Ami Fadia tells investors in a research note that she is "incrementally positive" on the state of the generics industry following investor meetings with the management teams from Outperform-rated Amneal (AMRX), Pfenex and Teligent. Fadia says a key takeaway from the teams is that the FDA is placing additional emphasis on reviewing and approving complex generics, and while there is starting to be more first-to-market approvals, there are also more approvals for the second and third generic entrants. Additionally, Fadia says the complex generic opportunity will likely be characterized by a slower-than-typical launch ramp, but also extended duration of meaningful financial contribution due to less overall competitors vs that for oral-solid generics and that while companies still regard biosimilar assets as attractive, the low penetration for biosimilar Remicade in the U.S., Mylan's (MYL) slow start with Fulphila and extended litigation timelines mean management teams looking to participate in this space are taking a more prudent approach and minimizing their upfront investment.
09/06/18
WELS
09/06/18
NO CHANGE
WELS
Teva, Mylan weakness related to low multiple in Sandoz sale, says Wells Fargo
Wells Fargo analyst David Maris attributes today's weakness in shares of generic drugmakers Teva (TEVA) and Mylan (MYL) to the low sales multiple at which Novartis' (NVS) Sandoz unit is selling a portfolio of generic and branded products to Aurobindo. While Teva and Mylan clearly have very different businesses than the largely commodity and dermatology portfolio Sandoz is selling for $900M, Maris believes some investors are looking at the deal as a proxy for what the commodity portions of their U.S. businesses might be worth, he tells investors. Maris, who has previously voiced caution about generics and generic drug pricing, sees Novartis' deal as another indication that the environment remains challenging.
08/30/18
GDHS
08/30/18
NO CHANGE
GDHS
Gordon Haskett questions Perrigo tie-up potential following call postponement
In a report published on August 20, Gordon Haskett analyst Don Bilson noted that Mylan (MYL) once claimed that it could generate $800M of synergies from a deal with Perrigo (PRGO) and while that dollar figure may no longer be relevant, the same logic may still be reasonably intact. At that time, he'd also pondered whether Mylan's failed attempt to acquire Perrigo in 2015-16 could be put back together given the troubles facing both companies. Gordon Haskett has flagged to investors that last night Perrigo postponed its investor event to discuss its long-term consumer growth strategies and key operational initiatives, previously planned as a conference call for September 25. Management had emphasized the event over 10 times on its earnings call just 3 weeks ago, the firm also noted.
08/28/18
HCWC
08/28/18
INITIATION
Target $28
HCWC
Buy
Coherus Biosciences initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Jason Kolbert started Coherus Biosciences (CHRS) with a Buy rating and $28 price target. The analyst expects approval of the company's Udencya in both the U.S. and Europe this year. His confidence level is driven by a positive recommendation from the European Committee for Medicinal Products for Human Use in July for marketing authorization of Udencya, a biosimilar compound targeting febrile neutropenia. Coherus announced that the committee reviewed all the new immunogenicity data that were required for the U.S. re-submission too, so the EU recommendation for approval adds a measure of confidence in support of U.S. approval, Kolbert tells investors in a research note. A year-end approval should position Udencya as the second biosimilar in the $4B U.S. marketplace behind Mylan (MYL), which should be launching its product following approval in June, the analyst adds.

TODAY'S FREE FLY STORIES

SMBC

Southern Missouri Bancorp

$36.25

0.03 (0.08%)

17:32
10/22/18
10/22
17:32
10/22/18
17:32
Earnings
Southern Missouri Bancorp reports Q3 EPS 76c, consensus 69c »

Reports Q3 provision for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMST

TimkenSteel

$12.19

-0.12 (-0.97%)

17:30
10/22/18
10/22
17:30
10/22/18
17:30
Hot Stocks
Breaking Hot Stocks news story on TimkenSteel »

Luminus Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

CEMI

Chembio Diagnostics

$9.68

-0.05 (-0.51%)

17:27
10/22/18
10/22
17:27
10/22/18
17:27
Syndicate
Chembio Diagnostics files to sell $25M of common stock »

Canaccord Genuity and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

SLM

Sallie Mae

$10.58

(0.00%)

17:23
10/22/18
10/22
17:23
10/22/18
17:23
Hot Stocks
Sallie Mae reports Q3 net interest margin up 15bps at 6.00% »

Q3 Private education loan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

SLM

Sallie Mae

$10.58

(0.00%)

17:22
10/22/18
10/22
17:22
10/22/18
17:22
Earnings
Sallie Mae raises FY18 core EPS view to $1.02-$1.03 from 99c-$1.01 »

Consensus$1.02. Raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

SLM

Sallie Mae

$10.58

(0.00%)

17:19
10/22/18
10/22
17:19
10/22/18
17:19
Earnings
Sallie Mae reports Q3 adjusted EPS 23c, consensus 24c »

Reports Q3 NII $356.6M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

BA

Boeing

$355.98

-0.3 (-0.08%)

17:17
10/22/18
10/22
17:17
10/22/18
17:17
Hot Stocks
Correction: Boeing maintains quarterly dividend of $1.71 »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

JOE

Saint Joe Co.

$15.08

-0.14 (-0.92%)

, MAR

Marriott

$111.49

-0.58 (-0.52%)

17:15
10/22/18
10/22
17:15
10/22/18
17:15
Hot Stocks
St. Joe Company, InterMountain break ground on New Towneplace Suites Hotel »

The St. Joe Company (JOE)…

JOE

Saint Joe Co.

$15.08

-0.14 (-0.92%)

MAR

Marriott

$111.49

-0.58 (-0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

RNST

Renasant

$35.44

-1.1 (-3.01%)

17:11
10/22/18
10/22
17:11
10/22/18
17:11
Earnings
Renasant reports Q3 adjusted EPS 61c, consensus 77c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Dec

IAG

IAMGold

$3.84

-0.13 (-3.27%)

17:09
10/22/18
10/22
17:09
10/22/18
17:09
Hot Stocks
IAMGold announces positive results from a feasibility study for Senegal project »

IAMGOLD announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

HWBK

Hawthorn Bancshares

$23.20

-0.27 (-1.15%)

17:09
10/22/18
10/22
17:09
10/22/18
17:09
Hot Stocks
Breaking Hot Stocks news story on Hawthorn Bancshares »

Endeavour Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNBC

Green Bancorp

$19.34

-0.7 (-3.49%)

17:07
10/22/18
10/22
17:07
10/22/18
17:07
Earnings
Green Bancorp reports Q3 EPS 49c, consensus 47c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

VBTX

Veritex

$24.43

-1.07 (-4.20%)

17:06
10/22/18
10/22
17:06
10/22/18
17:06
Earnings
Veritex reports Q3 core EPS 34c, consensus 46c »

Reports Q3 tangible book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

IBTX

Independent Bank

$56.47

-3.06 (-5.14%)

17:04
10/22/18
10/22
17:04
10/22/18
17:04
Earnings
Independent Bank reports Q3 EPS $1.20, consensus $1.20 »

Net interest income was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

BRO

Brown & Brown

$29.12

0.27 (0.94%)

17:03
10/22/18
10/22
17:03
10/22/18
17:03
Hot Stocks
Breaking Hot Stocks news story on Brown & Brown »

Brown & Brown reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 02

    Nov

  • 14

    Nov

SFNC

Simmons First National

$25.62

-0.78 (-2.95%)

17:03
10/22/18
10/22
17:03
10/22/18
17:03
Hot Stocks
Breaking Hot Stocks news story on Simmons First National »

Simmons First National…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 26

    Nov

CR

Crane

$87.33

-0.28 (-0.32%)

17:03
10/22/18
10/22
17:03
10/22/18
17:03
Earnings
Crane raises FY18 EPS ex-items view to $5.80-$5.90 from $5.60-$5.80 »

Consensus $5.75. Raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 05

    Dec

  • 06

    Dec

GNBC

Green Bancorp

$19.34

-0.7 (-3.49%)

17:02
10/22/18
10/22
17:02
10/22/18
17:02
Earnings
Green Bancorp reports Q3 non-GAAP EPS 49c, consensus 47c »

Reports Q3 provision for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

SFNC

Simmons First National

$25.62

-0.78 (-2.95%)

17:02
10/22/18
10/22
17:02
10/22/18
17:02
Earnings
Simmons First National reports Q3 core EPS 61c, consensus 58c »

Reports Q3 net interest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 26

    Nov

CR

Crane

$87.33

-0.28 (-0.32%)

17:02
10/22/18
10/22
17:02
10/22/18
17:02
Earnings
Crane reports Q3 EPS ex-items $1.62, consensus $1.46 »

Reports Q3 revenue $856M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 05

    Dec

  • 06

    Dec

BRO

Brown & Brown

$29.12

0.27 (0.94%)

17:01
10/22/18
10/22
17:01
10/22/18
17:01
Earnings
Brown & Brown reports Q3 adjusted EPS 38c, consensus 34c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 02

    Nov

  • 14

    Nov

NBTB

NBT Bancorp

$36.29

-0.57 (-1.55%)

16:54
10/22/18
10/22
16:54
10/22/18
16:54
Hot Stocks
NBT Bancorp raises quarterly dividend to 26c from 25c per share »

The dividend will be paid…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBTB

NBT Bancorp

$36.29

-0.57 (-1.55%)

16:54
10/22/18
10/22
16:54
10/22/18
16:54
Earnings
NBT Bancorp reports Q3 adjusted EPS 68c, consensus 65c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PERY

Perry Ellis

$27.50

(0.00%)

16:51
10/22/18
10/22
16:51
10/22/18
16:51
Hot Stocks
Perry Ellis announces completion of its acquisition in $437M transaction »

Perry Ellis International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

FBK

FB Financial

$33.54

-1.36 (-3.90%)

16:51
10/22/18
10/22
16:51
10/22/18
16:51
Earnings
FB Financial reports Q3 adjusted EPS 68c, consensus 72c »

President and Chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 05

    Nov

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

  • 05

    Dec

  • 06

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.